1. Clinical Pearls on Hot Topics in MS

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Brain Health as the Underlying Goal of Therapy in Multiple Sclerosis

5. Treatment in MS

6. Treatment Goal: Brain Health

7. Brain Health Goals

8. Domains of Brain Health

9. Minimizing MS Damage to the Brain

10. Promote Wellness and Control Environmental Factors

11. Promote Wellness and Control Environmental Factors (cont)

12. Minimizing Comorbidities in MS

13. Concluding Remarks

14. Strategies for Maintaining Brain Health in RRMS

15. Brain Health and Cognitive Reserve

16. Brain Size and Cognition

17. Comorbidities in MS

18. Common Comorbidities

19. Impact of Comorbidities

20. Comorbidities and Treatment Considerations

21. Strategies to Optimize Brain Health

22. Defining the Role of Brain Health in Progressive MS

23. MS Treatment Goals

24. Markers of Brain Health

25. Markers of Brain Health (cont)

26. Neurologic Reserve

27. Brain Reserve and Capacity to Accommodate Injury Evidence From AD

28. Cognitive Reserve

29. Ocrelizumab Brain Volume Reduction in RRMS

30. Alemtuzumab Brain Volume Reduction in RRMS

31. Ocrelizumab in PPMS

32. Conclusions

33. Shared Decision Making in Multiple Sclerosis

34. Approach to the Treatment of MS

35. DMTs for the Treatment of MS

36. Treatment Decision Making

37. Adherence in MS

38. Setting Realistic Expectations

39. Decision-Making Preferences in MS

40. Finding the Value Proposition of Modern MS Therapeutics

41. DMT Treatments and Cost

42. Economic Perspective: Value of Goods

43. Fingolimod vs IFNβ-1a in RRMS

44. Early initiation of Fingolimod Treatment in RRMS

45. Natalizumab vs Fingolimod in RRMS

46. Timing of High-Efficacy Therapies

47. Ocrelizumab in RRMS and PPMS

48. Alemtuzumab in RRMS

49. Cladribine in RRMS

50. Concluding Remarks

51. Abbreviations

52. Abbreviations (cont)